Figure 2.
Figure 2. HuMab VN18 inhibits platelet adhesion from whole blood to a plasma-derived clot under flow. Perfusion was performed for 5 minutes at a shear rate of 500 s–1. Coverslips were processed for light microscopic evaluation (original magnification × 250) and quantified. (A) Image of platelet adhesion on a plasma clot. The surface is covered for 34% ± 7% with platelets. (B) Inhibition of platelet adhesion in the presence of huMab VN18 (16 μg/mL) to 17% ± 2% surface coverage. (C) A control huMab did not affect platelet adhesion. Bar represents 25 μm.

HuMab VN18 inhibits platelet adhesion from whole blood to a plasma-derived clot under flow. Perfusion was performed for 5 minutes at a shear rate of 500 s–1. Coverslips were processed for light microscopic evaluation (original magnification × 250) and quantified. (A) Image of platelet adhesion on a plasma clot. The surface is covered for 34% ± 7% with platelets. (B) Inhibition of platelet adhesion in the presence of huMab VN18 (16 μg/mL) to 17% ± 2% surface coverage. (C) A control huMab did not affect platelet adhesion. Bar represents 25 μm.

Close Modal

or Create an Account

Close Modal
Close Modal